Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
Following a review that identified the practical use of haloperidol in patients with delirium is variable, this reminder has been issued to emphasise need for special caution when using it in the elderly, who are at an increased risk of adverse neurological and cardiac effects.
Source:
Medicines and Healthcare products Regulatory Agency
Resource links:
Review of the use of haloperidol in elderly patients with acute delirium
SPS commentary:
The MHRA has published a Public Assessment Report, detailing the results of its review into the safety of haloperidol in the treatment of acute delirium in elderly patients. Although this did not identify any changes necessary to the existing strong warnings and precautions, it identified variable use of haloperidol in patients with delirium. The MHRA is therefore reminding healthcare professionals that special caution is needed when using it in this way; it should only be considered when non-drug methods are not effective and there are no other contraindications preventing its use. The lowest possible dose should be used for the shortest possible time and patients should be frequently reviewed and closely monitored.